Breaking News Instant updates and real-time market news.

SNDX

Syndax

$4.78

0.02 (0.42%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55

Syndax management to meet with B. Riley FBR

Meeting to be held in Boston on December 10 hosted by B. Riley FBR.

  • 10

    Dec

  • 14

    Dec

SNDX Syndax
$4.78

0.02 (0.42%)

10/26/18
HCWC
10/26/18
NO CHANGE
Target $23
HCWC
Buy
Syndax price target lowered to $23 from $30 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for Syndax Pharmaceuticals to $23 after the company announced that the Phase 3 E2112 trial did not achieve statistical significance for the first primary endpoint of progression-free survival. The analyst moved his launch timing estimates back 12 months as he believes the overall survival opportunity is still likely. He keeps a Buy rating on Syndax.
10/29/18
MSCO
10/29/18
DOWNGRADE
MSCO
Equal Weight
Syndax downgraded to Equal Weight from Overweight at Morgan Stanley
10/29/18
10/29/18
DOWNGRADE
Target $6

Equal Weight
Morgan Stanley downgrades Syndax to Equal Weight after breast cancer study miss
As previously reported, Morgan Stanley analyst David Lebowitz downgraded Syndax to Equal Weight from Overweight after the pivotal Phase 3 study that evaluated entinostat + exemestane for the treatment of HR+, HER2- breast cancer missed on its first primary endpoint of progression free survival, or PFS. Though the company will pursue a registrational strategy for the drug in combination with Keytruda for the treatment of high baseline monocyte non-small cell lung cancer, he views that strategy as high risk, Lebowitz tells investors. He no longer expects entinostat to be launched in 2020, with the more likely launch in 2021 or later, the analyst added. He reduced his price target on Syndax shares to $6 from $24 after "dialing back" his expectations for entinostat.
10/29/18
OPCO
10/29/18
NO CHANGE
Target $13
OPCO
Outperform
Syndax price target lowered to $13 from $29 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Syndax to $13 from $29 after the company reported that the E2112 Phase 3 registration trial of entinostat plus exemestane in HR+/HER2- breast cancer did not meet statistical significance for PFS, nor for the third OS recently completed. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PRIM

Primoris

$21.34

-0.31 (-1.43%)

07:38
11/19/19
11/19
07:38
11/19/19
07:38
Hot Stocks
Primoris announces industrial awards valued over $30M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. expects cash, cash equivalents to fund operations into 4Q21 »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ECL

Ecolab

$191.28

-0.45 (-0.23%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. appoints Cassandra Choe-Juliak as acting CMO »

Affimed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Hot Stocks
Affimed N.V. plans preclinical studies for AFM28, AFM32 in 2020 »

Affimed selected two new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FB

Facebook

$197.45

2.38 (1.22%)

, BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

FB

Facebook

$197.45

2.38 (1.22%)

BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

LK

Luckin Coffee

$28.17

1.11 (4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

PTON

Peloton

$30.22

2.94 (10.78%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Recommendations
Peloton analyst commentary  »

JPMorgan reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MXL

MaxLinear

$19.84

-0.2 (-1.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Upgrade
MaxLinear rating change  »

MaxLinear upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$0.00

(0.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Conference/Events
Esterline management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:33
11/19/19
11/19
07:33
11/19/19
07:33
Hot Stocks
Affimed N.V. to initiate Phase 1/2a study of AFM24 in 1Q20 »

In October 2019, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MBRX

Moleculin Biotech

$1.04

(0.00%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Hot Stocks
Moleculin Biotech reports preliminary data from clinical trial of WP1220 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGYI

Youngevity

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Recommendations
Youngevity analyst commentary  »

Youngevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$38.84

-1.72 (-4.24%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$58.35

0.1 (0.17%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Upgrade
Ventas rating change  »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Earnings
Affimed N.V. reports Q3 EPS (EUR0.17) vs. (EUR0.19) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PGNY

Progyny

$24.89

1.095 (4.60%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CINF

Cincinnati Financial

$107.85

0.84 (0.78%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Conference/Events
Cincinnati Financial management to meet with Buckingham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TSM

TSMC

$53.41

0.12 (0.23%)

, RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

07:30
11/19/19
11/19
07:30
11/19/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSM

TSMC

$53.41

0.12 (0.23%)

RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$145.61

-0.75 (-0.51%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$414.70

7.7 (1.89%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Conference/Events
Chemed management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

VRCA

Verrica Pharmaceuticals

$14.35

-0.35 (-2.38%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Hot Stocks
Verrica Pharmaceuticals announces passing of board member Glenn Oclassen »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$103.80

2.31 (2.28%)

07:28
11/19/19
11/19
07:28
11/19/19
07:28
Recommendations
Fortinet analyst commentary  »

Fortinet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

AVGO

Broadcom

$310.95

-1.86 (-0.59%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Upgrade
Broadcom rating change  »

Broadcom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CGC

Canopy Growth

$14.21

-1.115 (-7.28%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Conference/Events
Canopy Growth management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CURR

CURE Pharmaceutical

$0.00

(0.00%)

, CNPOF

Canopy Rivers

$0.00

(0.00%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Hot Stocks
CURE Pharmaceutical appoints John Bell to board of directors »

CURE Pharmaceutical…

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CNPOF

Canopy Rivers

$0.00

(0.00%)

CGC

Canopy Growth

$14.21

-1.115 (-7.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.